Roundup of Antibody Biotech Deals in April 2026

April 2026 activity saw consolidation in the ADC space, continued expansion of next-generation antibody formats (including DACs and trispecifics), and strong financing for platform-driven oncology innovation. Strategic M&A and high-value partnerships highlighted sustained interest in complex biologics and targeted delivery technologies. 

🔍 April Deal Signals

1. M&A activity with a focus on ADC platforms and oncology pipelines

2. Variations on antibody-drug conjugates, like dual-payload ADCs and degrader-antibody conjugates (DACs)

3. Strategic interest in radiopharmaceutical antibodies and combination biologic approaches

4. Further multispecific formats, including trispecific antibodies targeting complex disease biology

5. Sustained investor support for platform and early clinical-stage companies, especially in oncology and immunology

💰 Mergers & Acquisitions (M&As)

• Gilead × Tubulis – Acquisition to add TUB-040, a NaPi2b-targeting ADC for ovarian cancer, along with a next-generation ADC platform; total deal value up to $5B.

• Eli Lilly × CrossBridge Bio – Acquisition to advance dual-payload ADC technologies; deal valued at $300M.

• Korsana Biosciences × Cyclerion Therapeutics – Merger agreement supported by $380M private investment to advance CNS-targeting shuttled antibodies.

🤝 Strategic Collaborations & Licensing

• C4 Therapeutics × Roche – Collaboration on degrader-antibody conjugates (DACs), with potential value up to $1B.

• Telix × Regeneron – Strategic partnership to develop radiopharmaceutical antibody therapies for solid tumors; potential deal value of $2.1B.

• Huahui Health × BeOne Medicines – Global licensing and collaboration agreement for HH160, a trispecific antibody; total deal value up to $2B.

• Cue Biopharma × Ascendant Health Sciences – Exclusive license for a dual-mechanism anti-IgE antibody targeting allergic diseases; deal value up to $691M.

• Boehringer Ingelheim × Zai Lab – Collaboration on DLL3-targeting T-cell engager and ADC combination therapies for neuroendocrine cancers.

💵 Financings & Company Launches

• Stipple Bio – Emerged from stealth with $100M Series A to advance STP-100, a novel ADC, and a precision oncology pipeline based on its pointillist platform.

• Sidewinder Therapeutics – Raised $137M Series B to develop bispecific ADCs targeting receptor co-complexes in solid tumors.

• First Tracks Biotherapeutics – Launched with $180M to advance antibody therapeutics targeting immune pathways in autoimmune and inflammatory diseases; lead program is a CD122 antagonist.

• Adcendo – Completed $75M Series C to support clinical development of its ADC pipeline targeting cancers with high unmet need.

• Alloy Therapeutics – Secured $40M Series E to scale its platform from antibody discovery to tech-enabled biotech infrastructure.

• Tacalyx – Raised €11M to advance TCX-201, a TACA-targeting ADC for gastrointestinal and other solid tumors.